ScoreWhy is Editas Medicine, Inc. ?
1
Poor long term growth as Net Sales has grown by an annual rate of 3.60% and Operating profit at -1.19% over the last 5 years
2
The company has declared Negative results for the last 4 consecutive quarters
- NET SALES(9M) At USD 38.84 MM has Grown at -37.05%
- INTEREST(9M) At USD 4.24 MM has Grown at inf%
- OPERATING CASH FLOW(Y) Lowest at USD -201.36 MM
3
Risky - Negative EBITDA
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of 0.42%, its profits have fallen by -19.3%
4
High Institutional Holdings at 84.49%
- These investors have better capability and resources to analyse fundamentals of companies than most retail investors.
5
Underperformed the market in the last 1 year
- The stock has generated a return of 0.42% in the last 1 year, much lower than market (S&P 500) returns of 12.33%
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to Editas Medicine, Inc. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Editas Medicine, Inc. for you?
High Risk, Low Return
Absolute
Risk Adjusted
Volatility
Editas Medicine, Inc.
22.73%
-0.40
138.93%
S&P 500
13.22%
0.61
20.17%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
3.60%
EBIT Growth (5y)
-1.19%
EBIT to Interest (avg)
-167.40
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-3.33
Sales to Capital Employed (avg)
0.24
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
84.49%
ROCE (avg)
0
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
2.56
EV to EBIT
0.23
EV to EBITDA
0.24
EV to Capital Employed
0.33
EV to Sales
-1.34
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
142.55%
ROE (Latest)
-317.44%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Mildly Bullish
Dow Theory
No Trend
Mildly Bullish
OBV
No Trend
No Trend
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend17What is working for the Company
NET SALES(HY)
At USD 8.24 MM has Grown at 399.76%
RAW MATERIAL COST(Y)
Fallen by -126.85% (YoY
DEBT-EQUITY RATIO
(HY)
Lowest at -524.76 %
DEBTORS TURNOVER RATIO(HY)
Highest at 93.51 times
OPERATING PROFIT(Q)
Highest at USD -23.63 MM
PRE-TAX PROFIT(Q)
Highest at USD -27.15 MM
NET PROFIT(Q)
Highest at USD -27.15 MM
-13What is not working for the Company
NET SALES(9M)
At USD 38.84 MM has Grown at -37.05%
INTEREST(9M)
At USD 4.24 MM has Grown at inf%
OPERATING CASH FLOW(Y)
Lowest at USD -201.36 MM
ROCE(HY)
Lowest at -188.58%
CASH AND EQV(HY)
Lowest at USD 399.47 MM
Here's what is working for Editas Medicine, Inc.
Net Sales
At USD 8.24 MM has Grown at 399.76%
Year on Year (YoY)MOJO Watch
Sales trend is very positive
Net Sales (USD MM)
Operating Profit
Highest at USD -23.63 MM
in the last five periodsMOJO Watch
Near term Operating Profit trend is positive
Operating Profit (USD MM)
Pre-Tax Profit
Highest at USD -27.15 MM
in the last five periodsMOJO Watch
Near term Pre-Tax Profit trend is positive
Pre-Tax Profit (USD MM)
Pre-Tax Profit
At USD -27.15 MM has Grown at 45.19%
over average net sales of the previous four periods of USD -49.54 MMMOJO Watch
Near term Pre-Tax Profit trend is positive
Pre-Tax Profit (USD MM)
Net Profit
Highest at USD -27.15 MM
in the last five periodsMOJO Watch
Near term Net Profit trend is positive
Net Profit (USD MM)
Net Profit
At USD -27.15 MM has Grown at 45.19%
over average net sales of the previous four periods of USD -49.54 MMMOJO Watch
Near term Net Profit trend is positive
Net Profit (USD MM)
Debt-Equity Ratio
Lowest at -524.76 %
in the last five Semi-Annual periodsMOJO Watch
The company has been reducing its borrowing as compared to equity capital
Debt-Equity Ratio
Debtors Turnover Ratio
Highest at 93.51 times
in the last five Semi-Annual periodsMOJO Watch
Company has been able to sell its Debtors faster
Debtors Turnover Ratio
Raw Material Cost
Fallen by -126.85% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for Editas Medicine, Inc.
Interest
At USD 4.24 MM has Grown at inf%
over previous Semi-Annual periodMOJO Watch
Rising interest cost signifies increased borrowings
Interest Paid (USD MM)
Operating Cash Flow
Lowest at USD -201.36 MM
in the last three yearsMOJO Watch
The company's cash revenues from business operations are falling
Operating Cash Flows (USD MM)
Cash and Eqv
Lowest at USD 399.47 MM
in the last six Semi-Annual periodsMOJO Watch
Short Term liquidity is deteriorating
Cash and Cash Equivalents
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
